ArticleInternational journal of clinical and experimental pathology2017
p75NTR promotes survival of breast cancer resistant cells by regulating Bcl-2/Bax and MAPK pathway.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- p75Neurotoxicity research · 2022Article
- Upregulation of CD271 transcriptome in breast cancer promotes cell survival via NFκB pathway.Molecular biology reports · 2022Article
- Nerve growth factor receptor increases the tumor growth and metastatic potential of triple-negative breast cancer cells.Oncogene · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In breast cancer, the neurotrophin receptor p75NTR is a critical factor that promotes resistance to the drug, however, its mechanism of action remains unclear. In our study, the 10 cases of positive expressions of p75NTR were detected in 86 cases of breast cancer tissues, accounting for 11.6% of cases detected. The immunohistochemistry detection of p75NTR was in the cytoplasm and cell membrane. The expression of p75NTR was significantly associated with histological grade (P<0.01), however, not with the menopause, tumor size and lymph node metastasis. Western blot result showed that p75NTR protein was induced by overexpression in the multidrug-resistant breast cancer cell lines. After transfection of pcDNA3.1-p75NTR, MDA-MB-231/ADR-p75NTR cell cycle was arrested in G0/G1 phase. However, the number of cells in G0/G1 phase increased and decreased in S phase cells (P<0.05). Additionally, apoptosis rate decreased (P<0.05). The p75NTR overexpression increased the expression of MDR related protein and activated MAPK signaling pathway.
Indexed as
Identifiers
31966528PMC6966053W3026255446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.